A 2-Part, Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride in Healthy Adult Participants (Part 2)
Latest Information Update: 02 Nov 2024
Price :
$35 *
At a glance
- Drugs Trospium chloride/xanomeline (Primary) ; Omeprazole
- Indications Psychotic disorders; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Karuna Therapeutics
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.
- 30 Sep 2024 New trial record